All canine diagnoses

Your dog was diagnosed with Cutaneous Melanoma (Haired Skin). Common skin tumour. Majority (>80%) of cutaneous melanocytic tumours of the haired skin are benign melanocytomas. Malignant cutaneous melanomas of haired skin tend to behave less aggressively than oral melanomas, but a subset will metastasise. Compare 1 treatment option for dogs including Surgical Excision — with survival times, costs, and what to expect during treatment.

🐕

Cutaneous Melanoma (Haired Skin)

BreedsMiniature SchnauzerScottish TerrierStandard SchnauzerVizslaIrish SetterDoberman Pinscher
canine

Melanocytic

About This Cancer

Cutaneous melanoma of the haired skin arises from melanocytes in the skin's outer layers. Unlike oral melanoma, the majority (over 80%) of melanocytic skin tumours on haired skin are benign growths called melanocytomas. These benign tumours are typically small, dark, well-circumscribed lumps that are cured by simple surgical removal. A minority are truly malignant melanomas, and even these tend to behave less aggressively than oral melanomas, though a subset can metastasise. Determining whether a given melanocytic skin tumour is benign or malignant requires histopathological examination — the microscopic features including the mitotic index (how rapidly cells are dividing) and Ki-67 proliferation marker help predict behaviour. Miniature Schnauzers, Scottish Terriers, and Vizslas are among the breeds more commonly affected.

Modified WHO staging (adapted from oral melanoma)

No formally validated staging system specific to canine cutaneous melanoma. Prognostic assessment relies on histological features: Ki-67 index, mitotic count, nuclear atypia, depth of invasion, ulceration.

Prognostic Factors(3)
Ki-67 indexMost accurate prognostic predictor. Low Ki-67 associated with significantly longer survival.(Smedley et al., 2011)
Mitotic indexHigh mitotic count correlates with malignant behaviour and shorter survival(Smedley et al., 2011)
Tumour thickness and ulcerationIncreased thickness and ulceration associated with worse prognosis(Gillard et al., 2014)
Minimum Workup(5 steps)
1FNA or excisional biopsy with histopathology
2Ki-67 index assessment on histopathology
3Mitotic count per 10 HPF
4Regional lymph node assessment
5Thoracic radiographs if histologically malignant

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Surgical Excision
~45 mo
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.